David L Gold

US Patent:

7238786, Jul 3, 2007

Filed:

Jun 16, 2003

Appl. No.:

10/461878

Inventors:

David V. Gold - Metuchen NJ, US
David M. Goldenberg - Mendham NJ, US
Hans J. Hansen - Picayune MS, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

C07K 16/00

US Classification:

5303873, 530350, 530380, 530385, 5303871, 5303877, 5303881, 4241341, 4241351, 4241411, 4241551, 4241421, 4241781, 424 851, 435 79, 435188, 4353201

Abstract:

This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to chimeric PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.

US Patent:

8392417, Mar 5, 2013

Filed:

May 22, 2007

Appl. No.:

11/752152

Inventors:

David P. Gold - New York NY, US

International Classification:

G06F 17/30

US Classification:

707737, 705311

Abstract:

In a method for organizing information in a database, abstractions are separated from expressions of the abstractions to obtain a first set of information corresponding to the abstractions and a second set of information corresponding to at least one set of characteristics relating to the expressions of the abstractions. Each abstraction is arranged within the first set of information hierarchically within the database. Each set of characteristics relating to an expression of an abstraction within the second set of information is associated with an abstraction within the database.

US Patent:

8491896, Jul 23, 2013

Filed:

Aug 7, 2009

Appl. No.:

12/537803

Inventors:

David M. Goldenberg - Mendham NJ, US
Hans J. Hansen - Picayune MS, US
Chien-Hsing Chang - Dowingtown PA, US
David V. Gold - Metuchen NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

A61K 39/395

US Classification:

4241331, 5303871

Abstract:

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19. 9, DUPAN2, SPAN1, Nd2, B72. 3, and Leand Le(y) antibodies that bind to the Lewis antigens.

US Patent:

8574854, Nov 5, 2013

Filed:

Feb 13, 2012

Appl. No.:

13/371969

Inventors:

David V. Gold - Metuchen NJ, US
David M. Goldenberg - Mendham NJ, US

Assignee:

Immunomedics, Inc. - Morris Plains NJ

International Classification:

G01N 33/53

US Classification:

435 71, 5303871

Abstract:

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.

US Patent:

20110165072, Jul 7, 2011

Filed:

Jan 20, 2011

Appl. No.:

13/010129

Inventors:

David V. Gold - Metuchen NJ, US
David M. Goldenberg - Mendham NJ, US

Assignee:

IMMUNOMEDICS, INC. - Morris Plains NJ

International Classification:

A61K 49/00
A61K 51/10
G01N 33/574

US Classification:

424 149, 424 91, 424 96, 436501, 435 71

Abstract:

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

US Patent:

20130179457, Jul 11, 2013

Filed:

Mar 4, 2013

Appl. No.:

13/784433

Inventors:

David P. Gold - New York NY, US

International Classification:

G06F 7/24

US Classification:

707752

Abstract:

In a method for organizing information in a database, abstractions are separated from expressions of the abstractions to obtain a first set of information corresponding to the abstractions and a second set of information corresponding to at least one set of characteristics relating to the expressions of the abstractions. Each abstraction is arranged within the first set of information hierarchically within the database. Each set of characteristics relating to an expression of an abstraction within the second set of information is associated with an abstraction within the database.

US Patent:

50984195, Mar 24, 1992

Filed:

Jul 19, 1990

Appl. No.:

7/555259

Inventors:

David L. Gold - Mahwah NJ

Assignee:

Nantucket Industries, Incorporated - New York NY

International Classification:

A61F 1315
A41B 900
A41B 902

US Classification:

604396

Abstract:

An undergarment that retains urine and other body fluids comprises an upper, or body, portion made of a knitted fabric, and a lower, or crotch, portion made of a woven, non-woven or knitted fabric. The crotch portion is coated with a modified polyester urethane polymer which prevents passage of body fluids, yet allows for some of the body condensate to escape by moisture vapor transmission. Because the crotch material is coated, rather than laminated, the garment body and crotch portion can be assembled without using special sewing needles, methods or speeds.

US Patent:

20160090413, Mar 31, 2016

Filed:

Dec 8, 2015

Appl. No.:

14/962706

Inventors:

- Morris Plains NJ, US
David V. Gold - Metuchen NJ, US
Chien-Hsing Chang - Downingtown PA, US
Serengulam V. Govindan - Summit NJ, US
David M. Goldenberg - Mendham NJ, US

International Classification:

C07K 16/18
C07K 16/30
G01N 33/574
A61K 47/48

Abstract:

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.